EIC application for the development and commercialisation of InSingulo´s platform for drug discovery

Purpose and goal:

This project aims to strengthen InSingulo´s application for funding from the EIC Accelerator. Insingulo provides the most sensitive label-free biosensing technology for drug development. We are transitioning from R&D to sales, marketing, and production scale-up. We seek EIC support to improve the assay window for dissociation. As part of Vinnova´s support, CIVITTA Sweden will assist us with developing the EIC application.

Expected results and effects:

The project´s expected effects include a well-defined work plan and timeline tailored to EIC Accelerator requirements. A robust business plan, incorporating precise financial projections and an effective go-to-market strategy, will strengthen the application. Expert guidance from CIVITTA Sweden will ensure compliance and maximise application success. The outcome is a robust application ready for timely submission, enhancing the likelihood of securing funding.

Approach and implementation:

The project will be implemented over the course of ca. 18 weeks between 01/06/2024 and 30/09/2024. The work will be organised into three work packages: WP1 Detailed planning of specific work packages WP2 Business plan and go-to-market strategy WP3 Strong EIC application

The work packages will run in parallel and be executed by the InSingulo team and with the support of a qualified grant consultancy (WP1, WP2, WP3).